Adlai Nortye Signs Lilly and Merck KGaA Clinical Collaborations for AN4035-Cetuximab Combo
ANL has more than doubled off its 52-week low of $0.879 on elevated volume (1.8× avg).
Summary
Adlai Nortye signed clinical collaboration and supply agreements with Lilly and Merck KGaA to test AN4035 plus cetuximab in its ongoing global Phase I trial; both partners supply cetuximab at no cost.
Key Events · M&A and Partnerships · ANL
-
Lilly and Merck KGaA Collaborations Signed
Adlai Nortye entered clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany for cetuximab (ERBITUX) in the ongoing global Phase I trial of AN4035.
-
Cetuximab Supplied at No Cost
Lilly supplies cetuximab free of charge for U.S. trial sites; Merck KGaA supplies it free of charge for Australia and China sites, reducing Adlai Nortye's trial costs.
-
Combination Arm Added to Phase I
AN4035 will be evaluated as monotherapy and in combination with cetuximab in CEACAM5-enriched, RAS-addicted solid tumors, with the combination arm on a staggered start timeline.
-
No Financial Terms Disclosed
The agreements include no disclosed milestones, royalties, equity or upfront payments; Adlai Nortye remains the trial sponsor.
Analysis · ANL · Life Sciences
Adlai Nortye secured clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to test its lead ADC AN4035 alongside cetuximab (ERBITUX) in CEACAM5-enriched, RAS-addicted solid tumors. Both partners will supply cetuximab at no cost — Lilly for U.S. sites, Merck KGaA for Australia and China sites — which lowers trial cost and, more importantly, puts two global oncology players' drug on the same protocol as AN4035. That is external validation of the RASiCA platform and a potential path to broader combination data in colorectal, pancreatic and lung cancers. No financial terms, milestones or equity were disclosed, so the near-term impact is credibility and execution rather than cash. The combination arm starts on a staggered timeline behind monotherapy, so readout is still quarters away.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.4% of the 1981 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANL was trading at $12.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $700.6M. The 52-week trading range was $0.88 to $17.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.